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ABSTRACT (196 words) 
Objectives: Adjudication committees (ACs) are recommended in randomized controlled trials 
(RCTs) to standardize the assessment of events. We aimed to assess the reporting and 
functioning of ACs (synonyms: clinical event committee, endpoint committee) in clinical 
trials. 
Study Design and Setting: We searched 5 high-impact-factor medical journals for reports of 
RCTs with clinical event endpoints published between January 1, 2004 and December 31, 
2005.  
Results: ACs were reported in 33.4% of the 314 reports of RCTs. ACs were reported in 
29.6% of trials with low risk of misclassification (i.e., “hard” main outcome), in 47.5% of 
trials with medium risk of misclassification (i.e., subjective main outcome and intervention 
delivered in a blinded fashion) and in 31% of trials with high risk of misclassification (i.e., 
subjective main outcome without intervention delivered in a blinded fashion). Selected cases 
to be adjudicated consisted largely of events identified by site investigators (93.3%). Data 
provided to the AC was reported for 47.4% of ACs.  
Conclusion: Reporting of ACs is not fitted to the risk of biased misclassification. Important 
aspects of the functioning of ACs are insufficiently reported or raise methodological issues. 
We propose some recommendations for planning and reporting ACs in clinical trials. 
 
Key words: Randomized Controlled Trials, Adjudication committee, Clinical event 
committee, Endpoint committee, Classification bias, Recommendations.  
Running title: Adjudication Committees in Randomized Controlled Trials 
Word count:  2997 words 
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INTRODUCTION 
The main purpose of a randomized controlled trial is to obtain a valid estimate of the 
treatment effect. The process of outcome assessment has a direct impact on the study 
results[1]. Determining whether a patient has reached an event may be difficult if the decision 
involves some subjectivity or when the endpoints require the application of a complex 
definition. Moreover, when the intervention is not delivered in a blinded fashion, the risk of 
ascertainment bias is high[2].For this reason, the Food and Drug Administration (FDA)[2] 
and the European Medicine Agency (EMEA)[3] recommend assessment of events by 
adjudication committees (ACs) in guidelines published in November 2001 and July 2005, 
respectively.  
The EMEA defines an AC as a committee consisting of clinical experts in a specific 
clinical area whose aim is to harmonize and standardize endpoint assessment. Synonyms are 
"clinical endpoints committee," "clinical event committee," and "panel review committee." 
The importance of such committees has been outlined in several studies[1, 4-8] showing that 
the classification of events changed in about 20% to 30% of cases after assessment by an AC. 
These modifications could have an important impact on treatment effect estimates, as 
demonstrated by Naslund et al[6], who showed that a 4 member AC, after examining case 
report forms transmitted by local investigators, corrected misinterpretations in 28.3% of cases 
leading to significantly different results from the preliminary results provided by site 
investigators.  
There is no recommendation on how ACs should process to ascertain endpoints and 
little is known about what is reported in RCTs concerning the functioning of ACs (e.g., 
number of members in the AC, how cases to adjudicate are selected, and reviewing process). 
We systematically reviewed RCTs published in 2004 and 2005 in 5 high-impact-factor 
general medical journals to assess the reporting of ACs to ascertain clinical event endpoints 
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and to describe the reported process of adjudication.  
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MATERIAL AND METHODS 
 
Data sources and searches 
We performed a computerized search in MEDLINE (via PUBMED) to identify all reports of 
RCTs published in 2004 and 2005 in five high impact factor general medical journals (New 
England Journal of Medicine, Lancet, JAMA, Annals of Internal Medicine, BMJ) from 
January 1, 2004 to December 31, 2005 with “Randomized controlled trials” as limit. Our goal 
was not to be exhaustive but, rather, to
 
raise awareness of methodological issues concerning 
ACs. We chose these 5 journals because: 1) They publish a high number of RCTs in many 
medical areas; 2) They have a high impact factor which is a good
 
predictor of high 
methodological quality of journal articles[9]; 3) They are also considered as having a higher 
quality of reporting than the others[10, 11].  
Study selection 
One of us (A.D.) selected potentially relevant articles after screening titles, abstract and 
material and methods sections. Articles were included if the study was a RCT having an event 
as a primary or secondary outcome. An event was defined as an outcome that may or may not 
occur for each subject in the RCT, anytime during the study period. Trials reported as phase 1, 
2 or pilot studies or assessing the efficacy or safety of diagnostic or screening procedures 
were excluded, as were subgroup analyses, secondary analyses and follow-up studies from an 
RCT. Articles were screened for duplicate publication (i.e., the same trial described in several 
articles), and only the trial with the main results (i.e., the article reporting the results for the 
primary outcomes) was selected. When articles referred to a former publication for 
methodology (e.g., publication of the protocol), this publication was searched and also 
evaluated.  
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Data extraction 
We used a data collection form that had been developed after an extensive bibliography on the 
subject and previously tested by 2 reviewers (A.D, I.B) on a random sample of 10 reports 
published in 2003. One reviewer (A.D.) independently completed all the data extractions. A 
second member of the team (I.B.) reviewed a random sample of 30 articles to assess inter 
rater agreement. In case of discrepancies between the abstract and the full text, the reviewers 
relied on the full text. The reviewers were not blinded to the journal name and authors.  
Data were obtained from each article as specified below: 
1. Characteristics of the selected articles, including medical area, funding sources 
(public, private, both public and private, or unclear), type of treatment assessed 
(pharmacological, nonpharmacological, or both), number of centers involved, and 
sample size. We also assessed whether patients, care providers and outcome assessors 
were reported as blinded to the treatment arm.  
2. Description of the primary and secondary outcomes: Events were classified in several 
categories derived from previous studies[12-14]: death from all causes, death from a 
specific cause (e.g., cardiac death), non-fatal medical events involving a complex 
definition (e.g., myocardial infarction, stroke), non-fatal medical events whose 
diagnostic relies only on radiological tests (e.g., stent stenosis, myocardial 
revascularization), non-fatal medical events whose diagnosis relies only on biological 
tests (e.g., diabetes), therapeutic decision (e.g., angioplasty, blood transfusion). We 
also checked whether events were of the same medical area or needed the expertise of 
physicians from different fields such as myocardial infarction and stroke.  
3. Reporting and functioning of ACs: for each selected article, we looked for the 
reporting of an AC by searching all possible synonyms (e.g., adjudication committee, 
endpoint committee, clinical event committee, panel review committee) in the article 
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as well as in the appendix and acknowledgement sections, the online extra material 
and the published protocol if possible. For each article reporting an AC, we noted 
- Methods for selecting cases to adjudicate: we reported whether the AC assessed 
the endpoints for all patients included in the RCT or only patients suspected of 
having an event according to site investigators or whether other methods for 
tracking events such as national registries or development of a specific computer 
algorithm were used.  
- Type of information provided to the AC: we looked whether the information 
included the complete medical file for each patient, only some elements of the file 
or a standardized case report form; we also noted whether results of different tests 
were reported as being provided to the ACs.  
- Composition of the AC: we checked the size of the AC, the name of members, 
their field of skill and their training before adjudication began; we also noted 
whether the members of the AC were reported to be independent of the study or 
blinded to the treatment arm.  
- Reviewing process of the AC: We searched whether the outcomes to adjudicate 
were defined and reporting on the number of members reviewing each case and the 
process used to reach consensus. We checked for the reporting of a comparison 
between the results of the AC evaluation and the site investigators’ evaluation. 
 
Data analysis 
We classified all trials according to the risk of biased misclassification. This classification 
was based on previously published works[12-14]. Briefly, we assumed that the risk of 
misclassification depends on the type of events: whether or not it involves some subjectivity 
and on the blinding status of both participants and care providers[15-17]. Table 1 shows the 
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definitions of low, medium and high risk of biased misclassification. Descriptive statistics 
included frequencies and percentages. Inter rater agreement between the two assessors (A.D 
and I.B) was assessed with the use of Kappa coefficient. All analyses involved SAS version 
9.1 (SAS Institute).  
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RESULTS 
Characteristics of the selected articles  
A flowchart of the selection of articles is reported in the figure. Briefly, the electronic search 
yielded 636 citations. From this list, 338 potentially relevant articles were selected after 
screening titles and abstracts, and, finally, 314 articles were selected after the full text was 
read.  Inter rater agreement for the data extraction was overall correct: the lower kappa value 
was 0.6 (95% CI: 0.3, 0.9) and the higher, 1. 
An AC was reported in 105 articles (33.4%). Table 2 shows the reporting of ACs according to 
the characteristics of the trial: ACs were described in 81.3% of cardiovascular trial reports, 
28.6% of neurological trial reports, 15.4% of hematologic or oncologic trial reports and 
11.1% of gynecology or obstetric trial reports. An AC was reported in 41.8% of reports of 
trials with private funding support and 21.1% of those with public funding.  
 
Types of primary outcomes adjudicated 
An AC was reported to assess the primary outcomes in 84 articles (80%). The adjudicated 
primary outcomes was a composite endpoint for 53 articles (63.1%).Table 3 shows the type of 
events adjudicated as primary outcomes. The main primary composite outcomes that were 
adjudicated were: specific cause of mortality or non fatal medical event (22.6%), all cause 
mortality or non fatal medical event (20.7%) and specific cause of mortality or non fatal 
medical even or therapeutic decision (18.9%). Adjudicated non-composite primary outcomes 
included mainly non fatal medical events (57.7%).  
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Reporting of ACs according to the risk of biased misclassification 
When the risk of misclassification as defined in table 1 was low, the rate of reported AC was 
29.6%; when the risk of misclassification was medium, the rate of reported AC was 47.5% 
and when the risk of misclassification was high, the rate of reported AC was 31.0%.  In 
cardiology, ACs are used in 81.1% of studies having a low risk of biased misclassification, in 
86.2% of studies with a medium risk of biased misclassification and in 83.9% of studies with 
a high risk. In the other medical areas, ACs were reported in 11.4%; 31.4% and 16.2%, 
respectively. 
 
Functioning of the ACs 
Among the 105 articles reporting an AC, 97 articles reported one AC, 4 reported 2 ACs, 3 
reported 3 ACs and 1 reported 4 ACs. The functioning of the AC was consequently assessed 
for 118 ACs. 
 
Methods for selecting cases to adjudicate and information provided to the AC (Table 4) 
The method of selecting cases to adjudicate was reported for 88.1% of ACs described. 
Methods for selecting cases provided to the AC consisted largely of suspected events 
identified by site investigators (n=97, 93.3%), reported to be blinded in 61.9% of cases. Other 
methods included use of national registries of death (n=9, 8.6%), routine electrocardiography 
screening by core laboratories (5, 4.8%), adjudication of all patients (n=1, 1%) and use of a 
specific computer algorithm (n=1, 1%).  
The information provided to the AC was reported for 56 ACs (47.4%). This information 
included all medical files (n = 14; 25%), a standardized case report form (n = 13; 23.2%), 
results of tests and procedures performed (n = 17; 30.3%) and autopsy reports (n = 8; 14.3%). 
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Composition of the AC (Table 4) 
The composition of the AC was reported for 89% of ACs. The median number of adjudicators 
was 3 (interquartile range: 3, 6). Medical skill were reported for 35 ACs (33.3%); of them, 10 
ACs had members from different medical skills. For 6 ACs (5.7%), members were reported to 
be trained. For 89.3% of ACs, members were reported to be independent to the study and for 
52.4% blinded to the treatment allocated. Committee member names were reported in the 
acknowledgements or appendix (83.8%) or as the authors of the article (32.4%). 
 
Reviewing process (Table 4) 
For 55 ACs (46.6%), all outcomes adjudicated were defined, for 38 (32.2%) only some 
outcomes were defined and for 25 (21.2%) none was defined.  
Information related to the reviewing process was reported for 28.8% of the ACs. For 14 ACs 
(41.2%), the whole AC reviewed each case. For 21 ACs (61.8%), the method to reach 
consensus was reported, and for 12 (35.3%), a consensus was reached by the whole AC. 
Methods for assessing reliability of adjudication were reported for 12 ACs (10.4%) and 
included verification of data transmitted to the AC by independent monitors (n=7) and 
readjudication of a certain number of cases (n=4). For 7 ACs (9.6%), results of the 
adjudication process were provided to the data safety monitoring board.  
A comparison between event rates according to the AC and to site investigators was reported 
for only 7 ACs. For all of them, adjudicated outcomes were outcomes suspected by site 
investigators. ACs did not confirm the outcomes suspected by site investigators in a median of 
21% of cases (IQR: 18, 25).  
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DISCUSSION 
To our knowledge, this is the first survey identifying all RCTs with clinical events endpoints 
in high impact factor journals to assess the epidemiology and reporting of ACs. Even though 
the use of ACs is recommended to harmonize and standardize endpoint assessment, we found 
reporting of ACs in only 33.4% of reports of RCTs with clinical event endpoints. Our results 
also highlight that some important aspects of the functioning of ACs are insufficiently 
reported or raise methodological issues.  
We classified all the selected trials according to the risk of endpoint misclassification as 
defined by the type of event and by the blinding status of participants and care providers.  Our 
results highlight that, when the risk of misclassification is low, nearly one third of articles 
reported an AC. When the risk of misclassification is medium, the reporting of AC increases 
but, surprisingly, when the risk of misclassification is high, ACs are reported for only one 
third of articles. On the contrary, in cardiovascular trials, ACs are frequently reported 
whatever the risk of biased misclassification. These results underscore that ACs could be used 
more frequently especially when the risk of misclassification is high and more efficiently 
since they are expensive and time-consuming[18]. ACs were found to be more often reported 
in trials with private support than in trials with public support. This result can be explained by 
the high prevalence of ACs in cardiovascular trials and the major private funding of these 
trials.  
Our results also highlight that some important aspects of the functioning of ACs are 
insufficiently reported like details of the information provided to the AC. Space restriction 
required by some journals could be a reason for not reporting an AC and details concerning its 
functioning. Nevertheless, we believe that the description of an AC could be summarized 
briefly in one sentence in the article and other important details like the composition of the 
AC could be reported in an online appendix of the article. Information on how the AC 
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classifies events is important for readers to judge the risk of ascertainment bias since reporting 
an AC does not hamper from bias. Actually, some details on ACs that were well reported in 
the reports of RCTs raise methodological issues. Methods for selecting cases assessed by the 
AC mainly rely on the events identified and reported by site investigators. However, site 
investigators may fail to identify all events or can be biased if investigators are not blinded to 
the treatment allocated. The rates of events can vary considerably depending on whether 
committees merely confirm events identified by site investigators or whether they adjudicate 
all patients[5, 6]. Adjudicating all patients is difficult to achieve because of time and cost. 
However, some RCTs used systematic screening of patients by routine check of biochemical 
markers and electrocardiographic analyses by core laboratories[6, 19-21], which allow for 
identifying myocardial infarction unsuspected by site investigators. Some studies have also 
developed a specific computer algorithm to identify events[1, 22]. Mahaffey et al[1] showed 
that, using a computer algorithm, 270 cases of myocardial infarction (5.2% of all patients 
enrolled) were not identified by site investigators and 134 cases (2.6%) identified by site 
investigators were not confirmed by the AC.  
Information provided to the ACs to adjudicate events was insufficiently reported. Petersen et 
al[23] outlined the limits of medical records and death certificates because of inconstancies 
and omissions in the reporting of important details. Several sources of information provided 
to the AC could be well-kept medical files and results of routine tests and procedures. 
Moreover, in some studies, ACs could ask site investigators about additional information 
when members judge that insufficient data to draw conclusions is provided[6, 18, 24]. 
The optimal number of adjudicators is not known[6]. Walter et al[18] described a trade-off 
between the accuracy of adjudicated results and the financial effort required for the 
adjudication process. Using different models, the authors showed that a size of 3 was a good 
compromise to allow for a majority opinion. The field of medical skill was reported for only 
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one-third of ACs, and for most trial reports, we could not assess the ability of adjudicators to 
classify an event. In more than 50% of articles, outcomes adjudicated were of different 
medical areas, and we supposed that members of the AC had different medical skills. Because 
some events are more difficult to adjudicate than others[24], training or education of 
adjudicators is also important to report, thus allowing for high consistency of results. In the 
same way, agreement between adjudicators[25-27] could be assessed to verify that additional 
training is not needed. Finally, although blinding of the AC is an important issue, it was 
reported in only half of the articles.  
Little information has been published on the process of an AC. Nevertheless, some studies 
reported the need for consensus among adjudicators to resolve disagreements[18, 23]. To 
verify the integrity of their event rates, some studies used methods of quality assurance such 
as verification of all data collected by site investigators by independent monitors and 
readjudication of a certain number of cases to compare with their previous results [4, 28-30].  
All these findings highlight that adjudication of events in RCTs is complex and the 
functioning of ACs raises some issues. We propose some recommendations for the planning 
and reporting of ACs in RCTs (Table 5).  
 
Our study presents some limitations. First, our search was restricted to articles published in 5 
high-impact-factor medical journals and may not be representative of the entire literature. 
Second, discrepancies may exist between real applications and reported methods. Some 
deficiencies may simply appear because of poor reporting, which does not necessarily mean 
that the methods were not applied[31, 32].  
 
In conclusion, ACs could be used more efficiently since they are expensive and time 
consuming. Our findings highlight the need for improved planning and reporting of ACs in 
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RCTs having an event as the primary outcome. The practical recommendations may help 
researchers enhance the quality of clinical event assessment. 
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